Professor Anthony Davenport University positionProfessor Professor Anthony Davenport is pleased to consider applications from prospective PhD students. DepartmentsExperimental Medicine & Therapeutics and Department of Medicine Home pagehttps://emit.medschl.cam.ac.uk/people/... (personal home page) Research ThemeInterestsOur research group focuses on understanding the role of G-protein-coupled receptors (GPCRs, targets for about ~50% of current drugs) together with their transmitters in humans. We use in vitro pharmacology, to determine how these are altered with disease. Major interests include the role of apelin, Elabela and endothelin-1 in human pathophysiology. Previous research has focussed on other peptides including urotensin II, ghrelin, neuromedin U, kisspeptins, trace amines.Wider research interests are reflected through co-executive member of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification. This committee has oversight of medicines and tool compounds databases: GuidetoPharmacology https://www.guidetopharmacology.org/ GuidetoImmunoPharmacology https://www.guidetoimmunopharmacology.org/immuno/index.jsp GuidetoPharmacologyOfMalaria https://www.guidetopharmacology.org/malaria/gtmpHelpPage.jsp  Imaging endothelin receptors in the rat in vivo using positron emission tomography Click image to view full-size Research Focus
EquipmentCell culture Confocal microscopy Fluorescence microscopy FPLC/HPLC Image analysis Immunohistochemistry In vitro pharmacology Microscopy Orphan G-protein coupled receptors Positron Emission Tomography (PET) Quantitative receptor autoradiography Collaborators
Associated News ItemsKey publicationsBrame, AL, Maguire, JJ, Yang, BA, Dyson, A, Torella, R, Cheriyan, J, Singer, M, Glen, RC, Wilkinson, IB, Davenport, (2015), “Design, characterization and first-in-human study of the vascular actions of a novel ‘biased’ apelin receptor agonist ” Hypertension 65, 834-840 Irkle, A, Vesey;AT, Lewis; DY, Skepper, JN, Bird; JLE, Dweck; MR, Joshi; FR, Gallagher; FA, Warburton; EA, Bennett; MR, Brindle; KM, Newby, DE, Rudd, JH, Davenport, AP (2015), “Identifying active vascular micro-calcification by 18F-sodium fluoride positron emission tomography ” Nature Comms 6, 1-11 Clarke MCH, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR (2006), “Apoptosis of vascular smooth muscle cells is silent in normal arteries but induces vulnerable plaques in atherosclerosis” Nature Medicine 12:1075-1080 Singh G, Kuc RE, Maguire JJ, Fidock M, Davenport AP (2006), “The novel snake venom ligand Dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: down-regulation of natriuretic peptide receptor-A in heart failure” Circulation Research 99:183-190 Details Singh G, Maguire J J, Kuc R E, Wiley KE, Fidock M, Davenport AP (2004), “Identification and cellular localization of NPW (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW-23 radioligand binding and immunocytochemistry” Brain Research 1017:222-226 Publications2015Maguire JJ and Davenport AP (2015), “Endothelin receptors and their antagonists ” Seminars in nephrology 35,125-136 2014Cuhlmann S, Gsell W, Van der Heiden K, Habib J, Tremoleda JL, Khalil M, Turkheimer F, Meens MJ, Kwak BR, Bird J, Davenport AP, Clark J, Haskard D, Krams R, Jones H, Evans PC (2014), “In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer 18F-FEDAA1106.” Mol Imaging 13:1-10 Details Kuc RE, Carlebur M, Maguire JJ, Yang P, Long L, Toshner M, Morrell NW, Davenport AP (2014), “Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.” Life Sci Details Kuc RE, Maguire JJ, Siew K, Patel S, Derksen DR, Margaret Jackson V, O'Shaughnessey KM, Davenport AP (2014), “Characterization of [¹²?I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.” Life Sci 102(2):134-8 Details Maguire JJ and Davenport AP (2014), “Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12 British journal of pharmacology 171:5555-5572” Brit J Pharmacol 171:5555-5572 Maguire JJ, Jones KL, Kuc RE, Clarke MC, Bennett MR, Davenport AP (2014), “The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.” Cardiovasc Res 101(3):513-21 Details Ooi CY, Sutcliffe MP, Davenport AP, Maguire JJ (2014), “Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis.” Life Sci Details Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ, NC-IUPHAR (2014), “The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.” Nucleic Acids Res 42(Database issue):D1098-106 Details 2013Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ, CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen (2013), “The Concise Guide to PHARMACOLOGY 2013/14: overview.” Br J Pharmacol 170(8):1449-58 Details Astin R, Bentham R, Djafarzadeh S, Horscroft JA, Kuc RE, Leung PS, Skipworth JR, Vicencio JM, Davenport AP, Murray AJ, Takala J, Jakob SM, Montgomery H, Szabadkai G (2013), “No evidence for a local renin-angiotensin system in liver mitochondria.” Sci Rep 3:2467 Details Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Küsters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ (2013), “Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension.” Nat Genet 45(9):1055-60 Details Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ (2013), “International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands.” Pharmacol Rev 65(3):967-86 Details Davenport AP, Barton M (2013), “Themed section: endothelin.” Br J Pharmacol 168(2):279-82 Details Davenport AP, Harmar AJ (2013), “Evolving pharmacology of orphan GPCRs: IUPHAR Commentary.” Br J Pharmacol 170(4):693-5 Details Ling L, Maguire JJ, Davenport AP (2013), “Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.” Br J Pharmacol 168(2):283-95 Details Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V, Davenport AP, Peters JA, Spedding M, Harmar AJ, NC-IUPHAR (2013), “IUPHAR-DB: updated database content and new features.” Nucleic Acids Res 41(Database issue):D1083-8 Details Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA, Merritt A, Bassoni DL, Raab WJ, Quinn E, Wehrman TS, Davenport AP, Brown AJ, Green A, Wigglesworth MJ, Rees S (2013), “Screening ?-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.” J Biomol Screen 18(5):599-609 Details 2012Barton M, Davenport AP (2012), “The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011.” Life Sci 91(13-14):462-5 Details Davenport AP, Kuc RE (2012), “Cellular localization of receptors using antibodies visualized by light and dual labeling confocal microscopy.” Methods Mol Biol 897:239-60 Details Johnström P, Bird JL, Davenport AP (2012), “Quantitative phosphor imaging autoradiography of radioligands for positron emission tomography.” Methods Mol Biol 897:205-20 Details Johnström P, Fryer TD, Bird JL, Richards HK, Davenport AP (2012), “Dynamic in vivo imaging of receptors in small animals using positron emission tomography.” Methods Mol Biol 897:221-37 Details Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP (2012), “Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice.” Life Sci 91(13-14):716-22 Details Maguire JJ, Kuc RE, Davenport AP (2012), “Radioligand binding assays and their analysis.” Methods Mol Biol 897:31-77 Details Maguire JJ, Kuc RE, Davenport AP (2012), “Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.” Life Sci 91(13-14):681-6 Details Maguire JJ, Kuc RE, Pell VR, Green A, Brown M, Kumar S, Wehrman T, Quinn E, Davenport AP (2012), “Comparison of human ETA and ETB receptor signalling via G-protein and ?-arrestin pathways.” Life Sci 91(13-14):544-9 Details Mpamhanga CP, Sharman JL, Harmar AJ, NC-IUPHAR (2012), “How to use the IUPHAR receptor database to navigate pharmacological data.” Methods Mol Biol 897:15-29 Details Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP (2012), “The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.” Life Sci 91(13-14):743-8 Details 2011Davenport AP, Maguire JJ (2011), “Pharmacology of renal endothelin receptors.” Contrib Nephrol 172:1-17 Details Jones KL, Maguire JJ, Davenport AP (2011), “Chemokine receptor CCR5: from AIDS to atherosclerosis.” Br J Pharmacol 162(7):1453-69 Details Macaluso NJ, Pitkin SL, Maguire JJ, Davenport AP, Glen RC (2011), “Discovery of a competitive apelin receptor (APJ) antagonist.” ChemMedChem 6(6):1017-23 Details Maguire JJ, Kirby HR, Mead EJ, Kuc RE, d'Anglemont de Tassigny X, Colledge WH, Davenport AP (2011), “Inotropic action of the puberty hormone kisspeptin in rat, mouse and human: cardiovascular distribution and characteristics of the kisspeptin receptor.” PLoS One 6(11):e27601 Details 2010Bird JL, Izquierdo-Garcia D, Davies JR, Rudd JH, Probst KC, Figg N, Clark JC, Weissberg PL, Davenport AP, Warburton EA (2010), “Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis.” Atherosclerosis 210(2):388-91 Details D'Orléans-Juste P, Benigni A, Davenport AP, Pollock DM (2010), “Introduction.” Can J Physiol Pharmacol 88(6):v-vi Details Davenport AP, Daly C (2010), “Themed section: Imaging in pharmacology.” Br J Pharmacol 159(4):735-7 Details Davies JR, Izquierdo-Garcia D, Rudd JH, Figg N, Richards HK, Bird JL, Aigbirhio FI, Davenport AP, Weissberg PL, Fryer TD, Warburton EA (2010), “FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis.” Int J Cardiovasc Imaging 26(1):41-8 Details Johnström P, Fryer TD, Richards HK, Maguire JJ, Clark JC, Pickard JD, Davenport AP (2010), “Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver.” Br J Pharmacol 159(4):812-9 Details Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ (2010), “Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1.” Can J Physiol Pharmacol 88(6):644-51 Details Kirby HR, Maguire JJ, Colledge WH, Davenport AP (2010), “International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function.” Pharmacol Rev 62(4):565-78 Details Mitchell JD, Kuc RE, Maguire JJ, Davenport AP (2010), “Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation.” Vet J 186(1):106-9 Details Pitkin SL, Maguire JJ, Bonner TI, Davenport AP (2010), “International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function.” Pharmacol Rev 62(3):331-42 Details Pitkin SL, Maguire JJ, Kuc RE, Davenport AP (2010), “Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.” Br J Pharmacol 160(7):1785-95 Details 2009Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR, Greenhill SD, Hale VA, Sharman JL, Bonner TI, Catterall WA, Davenport AP, Delagrange P, Dollery CT, Foord SM, Gutman GA, Laudet V, Neubig RR, Ohlstein EH, Olsen RW, Peters J, Pin JP, Ruffolo RR, Searls DB, Wright MW, Spedding M (2009), “IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels.” Nucleic Acids Res 37(Database issue):D680-5 Details Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP (2009), “[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease.” Hypertension 54(3):598-604 Details Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP (2009), “International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature.” Pharmacol Rev 61(1):1-8 Details Mitchell JD, Maguire JJ, Davenport AP (2009), “Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.” Br J Pharmacol 158(1):87-103 Details 2008Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR (2008), “Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration.” Circ Res 102(12):1529-38 Details Johnström P, Clark JC, Pickard JD, Davenport AP (2008), “Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate and application to (18)F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography.” Nucl Med Biol 35(6):725-31 Details Maguire JJ, Kuc RE, Kleinz MJ, Davenport AP (2008), “Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function.” Peptides 29(5):735-42 Details Mitchell JD, Maguire JJ, Kuc RE, Davenport AP (2008), “Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system.” Cardiovasc Res Details 2007Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ (2007), “Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.” Nephrol Dial Transplant 22(11):3228-34 Details Mead EJ, Maguire JJ, Kuc RE, Davenport AP (2007), “Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system.” Br J Pharmacol 151(8):1143-53 Details Mead EJ, Maguire JJ, Kuc RE, Davenport AP (2007), “Kisspeptins are novel potent vasoconstrictors in humans, with a discrete localization of their receptor, G protein-coupled receptor 54, to atherosclerosis-prone vessels.” Endocrinology 148(1):140-7 Details Probst KC, Izquierdo D, Bird JL, Brichard L, Franck D, Davies JR, Fryer TD, Richards HK, Clark JC, Davenport AP, Weissberg PL, Warburton EA (2007), “Strategy for improved [(11)C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [(11)C]DAA1106.” Nucl Med Biol 34(4):439-46 Details 2006Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV (2006), “Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt.” Hypertension 48(2):286-93 Details Davenport AP, Maguire JJ (2006), “Endothelin.” Handb Exp Pharmacol (176 Pt 1):295-329 Details Gardiner SM, March JE, Kemp PA, Maguire JJ, Kuc RE, Davenport AP, Bennett T (2006), “Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation.” Br J Pharmacol 147(6):612-21 Details Johnström P, Rudd JH, Richards HK, Fryer TD, Clark JC, Weissberg PL, Pickard JD, Davenport AP (2006), “Imaging endothelin ET(B) receptors using [18F]-BQ3020: in vitro characterization and positron emission tomography (microPET).” Exp Biol Med (Maywood) 231(6):736-40 Details Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP (2006), “Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man.” Cardiovasc Res 69(1):227-35 Details Kuc RE, Maguire JJ, Davenport AP (2006), “Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient mice.” Exp Biol Med (Maywood) 231(6):741-5 Details Maguire JJ, Wiley KE, Kuc RE, Stoneman VE, Bennett MR, Davenport AP (2006), “Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin.” Exp Biol Med (Maywood) 231(6):806-12 Details Singh G, Davenport AP (2006), “Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system.” Br J Pharmacol 148(8):1033-41 Details 2005Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K (2005), “International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function.” Pharmacol Rev 57(4):541-6 Details Davenport AP, Kuc RE (2005), “Immunocytochemical localization of receptors using light and confocal microscopy with application to the phenotypic characterization of knock-out mice.” Methods Mol Biol 306:155-72 Details Davenport AP, Kuc RE (2005), “Radioligand-binding and molecular-imaging techniques for the quantitative analysis of established and emerging orphan receptor systems.” Methods Mol Biol 306:93-120 Details Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M, Harmar AJ (2005), “International Union of Pharmacology. XLVI. G protein-coupled receptor list.” Pharmacol Rev 57(2):279-88 Details Gardiner SM, March JE, Kemp PA, Davenport AP, Wiley KE, Bennett T (2005), “Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats.” J Pharmacol Exp Ther 312(1):53-60 Details Johnström P, Davenport AP (2005), “Imaging and characterization of radioligands for positron emission tomography using quantitative phosphor imaging autoradiography.” Methods Mol Biol 306:203-16 Details Johnström P, Fryer TD, Richards HK, Barret O, Davenport AP (2005), “Dynamic in vivo imaging of receptors in small animals using positron emission tomography.” Methods Mol Biol 306:217-32 Details Johnström P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC, Pickard JD, Davenport AP (2005), “Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo.” Br J Pharmacol 144(1):115-22 Details Kleinz MJ, Davenport AP (2005), “Emerging roles of apelin in biology and medicine.” Pharmacol Ther 107(2):198-211 Details Kleinz MJ, Skepper JN, Davenport AP (2005), “Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells.” Regul Pept 126(3):233-40 Details Maguire JJ, Davenport AP (2005), “Regulation of vascular reactivity by established and emerging GPCRs.” Trends Pharmacol Sci 26(9):448-54 Details 2004Davenport AP, Kuc RE (2004), “Down-regulation of ETA receptors in ETB receptor-deficient mice.” J Cardiovasc Pharmacol 44 Suppl 1:S276-8 Details Johnström P, Fryer TD, Richards HK, Barret O, Clark JC, Ohlstein EH, Pickard JD, Davenport AP (2004), “In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET).” J Cardiovasc Pharmacol 44 Suppl 1:S34-8 Details Kleinz MJ, Davenport AP (2004), “Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells.” Regul Pept 118(3):119-25 Details Kuc R, Davenport AP (2004), “Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera.” J Cardiovasc Pharmacol 44 Suppl 1:S224-6 Details Maguire J, Davenport AP (2004), “Alternative pathway to endothelin-converting enzyme for the synthesis of endothelin in human blood vessels.” J Cardiovasc Pharmacol 44 Suppl 1:S27-9 Details Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP (2004), “Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.” Peptides 25(10):1767-74 Details Singh G, Maguire JJ, Kuc RE, Fidock M, Davenport AP (2004), “Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry.” Brain Res 1017(1-2):222-6 Details Wiley KE, Davenport AP (2004), “Endothelin receptor pharmacology and function in the mouse: comparison with rat and man.” J Cardiovasc Pharmacol 44 Suppl 1:S4-6 Details Wiley KE, Davenport AP (2004), “CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.” Br J Pharmacol 143(4):508-14 Details 2003Davenport AP (2003), “Peptide and trace amine orphan receptors: prospects for new therapeutic targets.” Curr Opin Pharmacol 3(2):127-34 Details Davenport AP, Macphee CH (2003), “Translating the human genome: renaissance of cardiovascular receptor pharmacology.” Curr Opin Pharmacol 3(2):111-3 Details Kutzler MA, Molnar J, Schlafer DH, Kuc RE, Davenport AP, Nathanielsz PW (2003), “Maternal dexamethasone increases endothelin-1 sensitivity and endothelin a receptor expression in ovine foetal placental arteries.” Placenta 24(4):392-402 Details 2002Davenport AP (2002), “International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature.” Pharmacol Rev 54(2):219-26 Details Davenport AP, Battistini B (2002), “Classification of endothelin receptors and antagonists in clinical development.” Clin Sci (Lond) 103 Suppl 48:1S-3S Details Davenport AP, Kuc RE (2002), “Radioligand binding assays and quantitative autoradiography of endothelin receptors.” Methods Mol Biol 206:45-70 Details Davenport AP, Kuc RE (2002), “Analysis of endothelins by enzyme-linked immunosorbent assay and radioimmunoassay.” Methods Mol Biol 206:21-36 Details Davenport AP, Maguire JJ (2002), “Of mice and men: advances in endothelin research and first antagonist gains FDA approval.” Trends Pharmacol Sci 23(4):155-7 Details Johnström P, Harris NG, Fryer TD, Barret O, Clark JC, Pickard JD, Davenport AP (2002), “(18)F-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: radiosynthesis and in vivo imaging using microPET.” Clin Sci (Lond) 103 Suppl 48:4S-8S Details Katugampola SD, Davenport AP (2002), “Radioligand binding reveals chymase as the predominant enzyme for mediating tissue conversion of angiotensin I in the normal human heart.” Clin Sci (Lond) 102(1):15-21 Details Katugampola SD, Kuc RE, Maguire JJ, Davenport AP (2002), “G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors.” Clin Sci (Lond) 103 Suppl 48:171S-175S Details Katugampola SD, Maguire JJ, Kuc RE, Wiley KE, Davenport AP (2002), “Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system.” Can J Physiol Pharmacol 80(5):369-74 Details Maguire JJ, Davenport AP (2002), “Is urotensin-II the new endothelin?” Br J Pharmacol 137(5):579-88 Details Maguire JJ, Yu JC, Davenport AP (2002), “ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels.” Clin Sci (Lond) 103 Suppl 48:184S-188S Details Menon DK, Day D, Kuc RE, Downie AJ, Chatfield DA, Davenport AP (2002), “Arteriojugular endothelin-1 gradients in aneurysmal subarachnoid haemorrhage.” Clin Sci (Lond) 103 Suppl 48:399S-403S Details Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnström P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL (2002), “Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.” Circulation 105(23):2708-11 Details Télémaque-Potts S, Kuc RE, Maguire JJ, Ohlstein E, Yanagisawa M, Davenport AP (2002), “Elevated systemic levels of endothelin-1 and blood pressure correlate with blunted constrictor responses and downregulation of endothelin(A), but not endothelin(B), receptors in an animal model of hypertension.” Clin Sci (Lond) 103 Suppl 48:357S-362S Details Wiley KE, Davenport AP (2002), “Comparison of the effects of atherosclerosis and nitrate therapy on responses to nitric oxide and endothelin-1 in human arteries in vitro.” Clin Sci (Lond) 103 Suppl 48:124S-127S Details Wiley KE, Davenport AP (2002), “Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.” Br J Pharmacol 136(8):1146-52 Details 2001Davenport AP, Maguire JJ (2001), “The endothelin system in human saphenous vein graft disease.” Curr Opin Pharmacol 1(2):176-82 Details Docherty CC, Kalmar-Nagy J, Engelen M, Koenen SV, Nijland M, Kuc RE, Davenport AP, Nathanielsz PW (2001), “Effect of in vivo fetal infusion of dexamethasone at 0.75 GA on fetal ovine resistance artery responses to ET-1.” Am J Physiol Regul Integr Comp Physiol 281(1):R261-8 Details Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T (2001), “Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.” Br J Pharmacol 132(8):1625-9 Details Katugampola SD, Davenport AP (2001), “Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan.” Br J Pharmacol 134(7):1385-92 Details Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP (2001), “[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man.” Br J Pharmacol 132(6):1255-60 Details Katugampola SD, Pallikaros Z, Davenport AP (2001), “[125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis.” Br J Pharmacol 134(1):143-9 Details Maguire JJ, Kuc RE, Davenport AP (2001), “Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.” Br J Pharmacol 134(6):1360-6 Details Wiley KE, Davenport AP (2001), “Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery.” Br J Pharmacol 133(4):568-74 Details Wiley KE, Davenport AP (2001), “Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system.” Br J Pharmacol 132(1):213-20 Details 2000Katugampola SD, Davenport AP (2000), “Changes in ET(A)-, AT1- and AT2-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries.” J Cardiovasc Pharmacol 36(5 Suppl 1):S395-6 Details 1999Maguire JJ, Davenport AP (1999), “The therapeutic potential of PD156707 and related butenolide endothelin antagonists.” Expert Opin Investig Drugs 8(1):71-8 Details Maguire JJ, Davenport AP (1999), “Endothelin receptor expression and pharmacology in human saphenous vein graft.” Br J Pharmacol 126(2):443-50 Details Pierre LN, Davenport AP (1999), “Blockade and reversal of endothelin-induced constriction in pial arteries from human brain.” Stroke 30(3):638-43 Details Russell FD, Davenport AP (1999), “Evidence for intracellular endothelin-converting enzyme-2 expression in cultured human vascular endothelial cells.” Circ Res 84(8):891-6 Details Russell FD, Davenport AP (1999), “Secretory pathways in endothelin synthesis.” Br J Pharmacol 126(2):391-8 Details 1998Davenport AP, Kuc RE, Ashby MJ, Patt WC, Doherty AM (1998), “Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues.” Br J Pharmacol 123(2):223-30 Details Davenport AP, Kuc RE, Mockridge JW (1998), “Endothelin-converting enzyme in the human vasculature: evidence for differential conversion of big endothelin-3 by endothelial and smooth-muscle cells.” J Cardiovasc Pharmacol 31 Suppl 1:S1-3 Details Harland SP, Kuc RE, Pickard JD, Davenport AP (1998), “Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707.” Neurosurgery 43(4):890-8; discussion 898-9 Details Longmore J, Razzaque Z, Shaw D, Davenport AP, Maguire J, Pickard JD, Schofield WN, Hill RG (1998), “Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors.” Br J Clin Pharmacol 46(6):577-82 Details Maguire JJ, Davenport AP (1998), “Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease.” Br J Pharmacol 125(2):238-40 Details Maguire JJ, Davenport AP (1998), “PD156707: a potent antagonist of endothelin-1 in human diseased coronary arteries and vein grafts.” J Cardiovasc Pharmacol 31 Suppl 1:S239-40 Details Mockridge JW, Kuc RE, Huskisson NS, Barker PJ, Davenport AP (1998), “Characterization of site-directed antisera against endothelin-converting enzymes.” J Cardiovasc Pharmacol 31 Suppl 1:S35-7 Details Morcos SK, Dawson P, Pearson JD, Jeremy JY, Davenport AP, Yates MS, Tirone P, Cipolla P, de Haën C, Muschick P, Krause W, Refsum H, Emery CJ, Liss P, Nygren A, Haylor J, Pugh ND, Karlsson JO (1998), “The haemodynamic effects of iodinated water soluble radiographic contrast media: a review.” Eur J Radiol 29(1):31-46 Details Pierre LN, Davenport AP (1998), “Endothelin receptor subtypes and their functional relevance in human small coronary arteries.” Br J Pharmacol 124(3):499-506 Details Pierre LN, Davenport AP (1998), “Relative contribution of endothelin A and endothelin B receptors to vasoconstriction in small arteries from human heart and brain.” J Cardiovasc Pharmacol 31 Suppl 1:S74-6 Details Russell FD, Coppell AL, Davenport AP (1998), “In vitro enzymatic processing of radiolabelled big ET-1 in human kidney.” Biochem Pharmacol 55(5):697-701 Details Russell FD, Skepper JN, Davenport AP (1998), “Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme.” Circ Res 83(3):314-21 Details Russell FD, Skepper JN, Davenport AP (1998), “Endothelin peptide and converting enzymes in human endothelium.” J Cardiovasc Pharmacol 31 Suppl 1:S19-21 Details Russell FD, Skepper JN, Davenport AP (1998), “Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin.” J Cardiovasc Pharmacol 31(3):424-30 Details 1997Kohnen G, Mackenzie F, Collett GP, Campbell S, Davenport AP, Cameron AD, Cameron IT (1997), “Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies.” Placenta 18(2-3):173-80 Details Maguire JJ, Johnson CM, Mockridge JW, Davenport AP (1997), “Endothelin converting enzyme (ECE) activity in human vascular smooth muscle.” Br J Pharmacol 122(8):1647-54 Details Maguire JJ, Kuc RE, Davenport AP (1997), “Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors.” J Pharmacol Exp Ther 280(2):1102-8 Details Russell FD, Skepper JN, Davenport AP (1997), “Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography.” J Cardiovasc Pharmacol 29(6):820-6 Details 1996Bacon CR, Cary NR, Davenport AP (1996), “Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta.” Circ Res 79(4):794-801 Details Bacon CR, Davenport AP (1996), “Endothelin receptors in human coronary artery and aorta.” Br J Pharmacol 117(5):986-92 Details Collett GP, Kohnen G, Campbell S, Davenport AP, Jeffers MD, Cameron IT (1996), “Localization of endothelin receptors in human uterus throughout the menstrual cycle.” Mol Hum Reprod 2(6):439-44 Details Davenport AP, Hoskins SL, Kuc RE, Plumpton C (1996), “Differential distribution of endothelin peptides and receptors in human adrenal gland.” Histochem J 28(11):779-89 Details Karet FE, Davenport AP (1996), “Selective downregulation of ETA receptor mRNA in renal transplant recipients on cyclosporin A revealed by quantitative RT-PCR.” Nephrol Dial Transplant 11(10):1976-82 Details Karet FE, Davenport AP (1996), “Localization of endothelin peptides in human kidney.” Kidney Int 49(2):382-7 Details Maguire JJ, Kuc RE, Rous BA, Davenport AP (1996), “Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.” Br J Pharmacol 118(2):335-42 Details Peter MG, Davenport AP (1996), “Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.” Br J Pharmacol 117(3):455-462 Details Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP (1996), “Expression of endothelin peptides and mRNA in the human heart.” Clin Sci (Lond) 90(1):37-46 Details Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP (1996), “The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.” Br J Pharmacol 119(2):311-4 Details Russell FD, Davenport AP (1996), “Characterization of the binding of endothelin ETB selective ligands in human and rat heart.” Br J Pharmacol 119(4):631-6 Details 1995Ashby MJ, Plumpton C, Teale P, Kuc RE, Houghton E, Davenport AP (1995), “Analysis of endogenous human endothelin peptides by high-performance liquid chromatography and mass spectrometry.” J Cardiovasc Pharmacol 26 Suppl 3:S247-9 Details Bacon CR, Cary NR, Davenport AP (1995), “Distribution of endothelin receptors in atherosclerotic human coronary arteries.” J Cardiovasc Pharmacol 26 Suppl 3:S439-41 Details Bacon CR, Morrison JJ, O'Reilly G, Cameron IT, Davenport AP (1995), “ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242.” J Endocrinol 144(1):127-34 Details Cameron IT, Bacon CR, Collett GP, Davenport AP (1995), “Endothelin expression in the uterus.” J Steroid Biochem Mol Biol 53(1-6):209-14 Details Davenport AP, Kuc RE, Maguire JJ, Harland SP (1995), “ETA receptors predominate in the human vasculature and mediate constriction.” J Cardiovasc Pharmacol 26 Suppl 3:S265-7 Details Davenport AP, O'Reilly G, Kuc RE (1995), “Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.” Br J Pharmacol 114(6):1110-6 Details Harland SP, Kuc RE, Pickard JD, Davenport AP (1995), “Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas.” J Cardiovasc Pharmacol 26 Suppl 3:S408-11 Details Karet FE, Davenport AP (1995), “Comparative quantification of endothelin receptor mRNA in human kidney: new tools for direct investigation of human tissue.” J Cardiovasc Pharmacol 26 Suppl 3:S268-71 Details Kuc RE, Karet FE, Davenport AP (1995), “Characterization of peptide and nonpeptide antagonists in human kidney.” J Cardiovasc Pharmacol 26 Suppl 3:S373-5 Details Maguire JJ, Davenport AP (1995), “ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.” Br J Pharmacol 115(1):191-7 Details Maguire JJ, Kuc RE, Doherty AM, Davenport AP (1995), “Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors.” J Cardiovasc Pharmacol 26 Suppl 3:S362-4 Details Peter MG, Davenport AP (1995), “Delineation of endothelin receptors in human left ventricular smooth-muscle cells.” J Cardiovasc Pharmacol 26 Suppl 3:S355-7 Details Peter MG, Davenport AP (1995), “Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.” Br J Pharmacol 114(2):297-302 Details Pierre LN, Davenport AP (1995), “Autoradiographic study of endothelin receptors in human cerebral arteries.” J Cardiovasc Pharmacol 26 Suppl 3:S326-8 Details Plumpton C, Haynes WG, Webb DJ, Davenport AP (1995), “Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.” Br J Pharmacol 116(2):1821-8 Details Plumpton C, Haynes WG, Webb DJ, Davenport AP (1995), “Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans.” J Cardiovasc Pharmacol 26 Suppl 3:S34-6 Details Russell FD, Davenport AP (1995), “Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139.” J Cardiovasc Pharmacol 26 Suppl 3:S346-7 Details Yu JC, Davenport AP (1995), “Regulation of endothelin receptor expression in vascular smooth-muscle cells.” J Cardiovasc Pharmacol 26 Suppl 3:S348-50 Details Yu JC, Davenport AP (1995), “Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells.” Br J Pharmacol 114(2):551-7 Details Yu JC, Pickard JD, Davenport AP (1995), “Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells.” Br J Pharmacol 116(5):2441-6 Details 1994Davenport AP, Kuc RE, Fitzgerald F, Maguire JJ, Berryman K, Doherty AM (1994), “[125I]-PD151242: a selective radioligand for human ETA receptors.” Br J Pharmacol 111(1):4-6 Details Davenport AP, Kuc RE, Hoskins SL, Karet FE, Fitzgerald F (1994), “[125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.” Br J Pharmacol 113(4):1303-10 Details Davenport AP, Maguire JJ (1994), “Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?” Trends Pharmacol Sci 15(1):9-11 Details Gardiner SM, Kemp PA, March JE, Bennett T, Davenport AP, Edvinsson L (1994), “Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats.” Br J Pharmacol 112(2):477-86 Details Karet FE, Charnock-Jones DS, Harrison-Woolrych ML, O'Reilly G, Davenport AP, Smith SK (1994), “Quantification of mRNA in human tissue using fluorescent nested reverse-transcriptase polymerase chain reaction.” Anal Biochem 220(2):384-90 Details Karet FE, Davenport AP (1994), “Endothelin and the human kidney: a potential target for new drugs.” Nephrol Dial Transplant 9(5):465-8 Details Maguire JJ, Bacon CR, Fujimoto M, Davenport AP (1994), “Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors.” J Hypertens 12(6):675-80 Details Maguire JJ, Kuc RE, O'Reilly G, Davenport AP (1994), “Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.” Br J Pharmacol 113(1):49-54 Details Plumpton C, Kalinka S, Martin RC, Horton JK, Davenport AP (1994), “Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays.” Clin Sci (Lond) 87(2):245-51 Details 1993Cameron IT, Plumpton C, Champeney R, van Papendorp C, Ashby MJ, Davenport AP (1993), “Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium.” J Reprod Fertil 98(1):251-5 Details Davenport AP, O'Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A (1993), “Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle.” J Cardiovasc Pharmacol 22 Suppl 8:S22-5 Details Haynes WG, Davenport AP, Webb DJ (1993), “Endothelin: progress in pharmacology and physiology.” Trends Pharmacol Sci 14(6):225-8 Details Karet FE, Davenport AP (1993), “Human kidney: endothelin isoforms detected by HPLC with radioimmunoassay and receptor subtypes detected using ligands BQ123 and BQ3020.” J Cardiovasc Pharmacol 22 Suppl 8:S29-33 Details Karet FE, Kuc RE, Davenport AP (1993), “Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney.” Kidney Int 44(1):36-42 Details Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP (1993), “Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium.” Circ Res 72(3):526-38 Details O'Reilly G, Charnock-Jones DS, Cameron IT, Smith SK, Davenport AP (1993), “Endothelin-2 mRNA splice variants detected by RT-PCR in cultured human vascular smooth muscle and endothelial cells.” J Cardiovasc Pharmacol 22 Suppl 8:S18-21 Details O'Reilly G, Charnock-Jones DS, Morrison JJ, Cameron IT, Davenport AP, Smith SK (1993), “Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution.” Biochem Biophys Res Commun 193(3):834-40 Details Persidis A, Harcombe AA, Davenport AP, Kuc RE, Plumpton C, Weissberg PL (1993), “Isolation of human cardiac endothelin receptors by a peptide-receptor mobility shift assay.” Clin Sci (Lond) 85(2):169-73 Details Plumpton C, Champeney R, Ashby MJ, Kuc RE, Davenport AP (1993), “Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated.” J Cardiovasc Pharmacol 22 Suppl 8:S26-8 Details Sun B, Davenport AP, Brown MJ (1993), “Quantitative autoradiography reveals higher densities of specific calcitonin-gene-related peptide receptors in small intramyocardial compared with large epicardial coronary arteries.” Clin Sci (Lond) 84(1):55-60 Details 1992Cameron IT, Davenport AP, van Papendorp C, Barker PJ, Huskisson NS, Gilmour RS, Brown MJ, Smith SK (1992), “Endothelin-like immunoreactivity in human endometrium.” J Reprod Fertil 95(2):623-8 Details Howard PG, Plumpton C, Davenport AP (1992), “Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue.” J Hypertens 10(11):1379-86 Details Marciniak SJ, Plumpton C, Barker PJ, Huskisson NS, Davenport AP (1992), “Localization of immunoreactive endothelin and proendothelin in the human lung.” Pulm Pharmacol 5(3):175-82 Details Molenaar P, Kuc RE, Davenport AP (1992), “Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart.” Br J Pharmacol 107(3):637-9 Details Morton AJ, Davenport AP (1992), “Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b.” Brain Res 581(2):299-306 Details O'Reilly G, Charnock-Jones DS, Davenport AP, Cameron IT, Smith SK (1992), “Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle.” J Clin Endocrinol Metab 75(6):1545-9 Details 1991Cameron IT, Davenport AP, Brown MJ, Smith SK (1991), “Endothelin-1 stimulates prostaglandin F2 alpha release from human endometrium.” Prostaglandins Leukot Essent Fatty Acids 42(3):155-7 Details Davenport AP, Cameron IT, Smith SK, Brown MJ (1991), “Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography.” J Endocrinol 129(1):149-54 Details Davenport AP, Morton AJ (1991), “Binding sites for 125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells.” Brain Res 554(1-2):278-85 Details Davenport AP, Morton AJ, Brown MJ (1991), “Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney.” J Cardiovasc Pharmacol 17 Suppl 7:S152-5 Details Haining RE, Cameron IT, van Papendorp C, Davenport AP, Prentice A, Thomas EJ, Smith SK (1991), “Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues.” Hum Reprod 6(9):1200-5 Details Nunez DJ, Davenport AP, Brown MJ (1991), “Molecular aspects of atrial natriuretic factor physiology.” Ann Acad Med Singapore 20(1):19-25 Details van Papendorp CL, Cameron IT, Davenport AP, King A, Barker PJ, Huskisson NS, Gilmour RS, Brown MJ, Smith SK (1991), “Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta.” J Endocrinol 131(3):507-11 Details 1990Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, Nunez DJ, Capper SJ, Brown MJ (1990), “A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects.” Clin Sci (Lond) 78(3):261-4 Details Davenport AP, Augood SJ, Lawson DE, Emson PC (1990), “The use of quantitative immunocytochemistry (QICC) to measure calbindin D28k-like immunoreactivity in the rat brain.” Cell Mol Biol 36(1):1-11 Details Nunez DJ, Brown MJ, Davenport AP, Neylon CB, Schofield JP, Wyse RK (1990), “Endothelin-1 mRNA is widely expressed in porcine and human tissues.” J Clin Invest 85(5):1537-41 Details Nunez DJ, Davenport AP, Brown MJ (1990), “Atrial natriuretic factor mRNA and binding sites in the adrenal gland.” Biochem J 271(2):555-8 Details Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalfe JC (1990), “The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells.” Atherosclerosis 85(2-3):257-62 Details 1989Davenport AP, Hill RG, Hughes J (1989), “Quantitative analysis of autoradiograms.” Experientia Suppl 56:137-53 Details Davenport AP, Nunez DJ, Brown MJ (1989), “Binding sites for 125I-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography.” Clin Sci (Lond) 77(2):129-31 Details Davenport AP, Nunez DJ, Hall JA, Kaumann AJ, Brown MJ (1989), “Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans.” J Cardiovasc Pharmacol 13 Suppl 5:S166-70 Details Nunez DJ, Davenport AP, Emson PC, Brown MJ (1989), “A quantitative 'in-situ' hybridization method using computer-assisted image analysis. Validation and measurement of atrial-natriuretic-factor mRNA in the rat heart.” Biochem J 263(1):121-7 Details 1988Beresford IJ, Davenport AP, Sirinathsinghji DJ, Hall MD, Hill RG, Hughes J (1988), “Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors.” Neuroscience 27(1):129-43 Details Davenport AP, Hall MD (1988), “Comparison between brain paste and polymer [125I]standards for quantitative receptor autoradiography.” J Neurosci Methods 25(1):75-82 Details 1986Davenport AP, Evans PD (1986), “Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect, Schistocerca gregaria, revealed by radioimmunoassay.” Brain Res 383(1-2):319-22 Details 1983Mercer AR, Mobbs PG, Davenport AP, Evans PD (1983), “Biogenic amines in the brain of the honeybee, Apis mellifera.” Cell Tissue Res 234(3):655-77 Details |